Harnessing the Power of RNA Alternative Splicing

Biosplice is a biopharmaceutical company developing first-in-class therapies that harness RNA alternative splicing. The Company's scientific platform is based on biological discoveries that govern tissue specialization and enable elimination of harmful proteins using these small molecules.

Biosplice's leading drug is targeted to treat knee osteoarthritis with the goal of alleviating pain and the aim of restoring tissue balance and protecting from cartilage loss. Biosplice's clinical pipeline also focuses on oncology, with additionalvearly-stage programs in neurology and other areas of significant unmet medical needs.